$EYEG Target 2.90 for 44% Eyegate Pharmaceuticals (EYEG) said Wednesday it has completed its target enrollment of 21 patients in a mid-stage proof-of-concept study of PP-001 for ocular surface inflammation due to ocular surface diseases, including dry eye.
Topline data from the study are expected to be released in Q4, with
Key stats
About AB Corporate Bond ETF
Home page
Inception date
Dec 13, 2023
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Ordinary income
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
AllianceBernstein LP
Distributor
Foreside Fund Services LLC
EYEG seeks to maximize total return through an actively managed portfolio of corporate bonds. The fund primarily invests in USD-denominated, investment grade fixed income securities of any maturity or duration issued by US and foreign companies. To construct the portfolio, the fund adviser employs a dynamic multifactor approach that considers six broad proprietary categories: value, momentum, size, quality, carry, and volatility. The investment process also takes into account a bond’s credit quality and interest rate sensitivity. The fund may invest up to 10% of its net assets in debt securities rated below investment grade. The fund may also hold derivatives, such as options, futures contracts, forwards, or swaps for hedging and non-hedging purposes.
Classification
What's in the fund
Exposure type
Corporate
Stock breakdown by region
Top 10 holdings
EYEG Wedge Breakout + MACD CrossPrice consolidating atop the 200 SMA, and recently the 50 SMA. MACD bull cross, and RSI finding strong support on top of the 50 EMA of the RSI convey upside momentum bias (I find the 50 EMA on the 14 RSI to be very informative, I recommend you try it for yourself). I am looking for price to stay sup
70% profit target EYEGChart is starting to flip bullish on support at LTF's. Will be buying my way down and expecting this gap to close. A little more risk than I normally like to try (8-10%) but 70% run up looking nice and we're seeing lots of tech/bio stock boom lately.
Check my page for a handful of other 50+ % runu
Short the popEven with the fear of biotech companies flying high when they have successful trials, I like the short today. This is a preliminary study that provided very positive news, however the long term price deterioration of the stock points to a pullback and setbacks. This is speculative, thus good luck tr
EYEG - swing idea momentum gap playEYEG had news today so this helped the stock gain visibilty and momentum finance.yahoo.com
RISK / REWARD swing idea and gap play
Analysis:
RSI is at 53 (not oversold) but is in the area of accumulation.
MACD is moving in positive area
Gap Zone hasn't been filled completely
Daytrade idea: over
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related funds
Frequently Asked Questions
An exchange-traded fund (ETF) is a collection of assets (stocks, bonds, commodities, etc.) that track an underlying index and can be bought on an exchange like individual stocks.
EYEG trades at 35.11 USD today, its price has risen 0.16% in the past 24 hours. Track more dynamics on EYEG price chart.
EYEG net asset value is 35.07 today — it's risen 0.02% over the past month. NAV represents the total value of the fund's assets less liabilities and serves as a gauge of the fund's performance.
EYEG assets under management is 26.15 M USD. AUM is an important metric as it reflects the fund's size and can serve as a gauge of how successful the fund is in attracting investors, which, in its turn, can influence decision-making.
EYEG price has fallen by −0.40% over the last month, and its yearly performance shows a 0.57% increase. See more dynamics on EYEG price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 0.02% over the last month, showed a −0.64% decrease in three-month performance and has increased by 6.80% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by 0.02% over the last month, showed a −0.64% decrease in three-month performance and has increased by 6.80% in a year.
EYEG fund flows account for 1.79 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Since ETFs work like an individual stock, they can be bought and sold on exchanges (e.g. NASDAQ, NYSE, EURONEXT). As it happens with stocks, you need to select a brokerage to access trading. Explore our list of available brokers to find the one to help execute your strategies. Don't forget to do your research before getting to trading. Explore ETFs metrics in our ETF screener to find a reliable opportunity.
EYEG invests in bonds. See more details in our Analysis section.
EYEG expense ratio is 0.30%. It's an important metric for helping traders understand the fund's operating costs relative to assets and how expensive it would be to hold the fund.
No, EYEG isn't leveraged, meaning it doesn't use borrowings or financial derivatives to magnify the performance of the underlying assets or index it follows.
In some ways, ETFs are safe investments, but in a broader sense, they're not safer than any other asset, so it's crucial to analyze a fund before investing. But if your research gives a vague answer, you can always refer to technical analysis.
Today, EYEG technical analysis shows the buy rating and its 1-week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1-month rating EYEG shows the strong sell signal. See more of EYEG technicals for a more comprehensive analysis.
Today, EYEG technical analysis shows the buy rating and its 1-week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1-month rating EYEG shows the strong sell signal. See more of EYEG technicals for a more comprehensive analysis.
Yes, EYEG pays dividends to its holders with the dividend yield of 5.24%.
EYEG trades at a premium (0.12%).
Premium/discount to NAV expresses the difference between the ETF’s price and its NAV value. A positive percentage indicates a premium, meaning the ETF trades at a higher price than the calculated NAV. Conversely, a negative percentage indicates a discount, suggesting the ETF trades at a lower price than NAV.
Premium/discount to NAV expresses the difference between the ETF’s price and its NAV value. A positive percentage indicates a premium, meaning the ETF trades at a higher price than the calculated NAV. Conversely, a negative percentage indicates a discount, suggesting the ETF trades at a lower price than NAV.
EYEG shares are issued by Equitable Holdings, Inc.
EYEG follows the No Underlying Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
The fund started trading on Dec 13, 2023.
The fund's management style is active, aiming to outperform its benchmark index by actively selecting and adjusting assets. The goal is to achieve returns that exceed those of the index the fund tracks.